PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21838410-10	2011	RESULTS: Both co-primary objectives and the first two gated secondary objectives were achieved: compared with placebo, duloxetine significantly improved the mean MADRS total score, BPI average pain rating, SDS global functional impairment score, and remission of depression at 8-week endpoint (all p < 0.01).	Duloxetine Hydrochloride	119-129	bactericidal permeability increasing protein	Homo sapiens	181-184	
21838410-12	2011	The within-group MADRS remission rate was greater for duloxetine-treated patients with >=50% (versus <50%) improvement in BPI average pain (p < 0.001).	Duloxetine Hydrochloride	54-64	bactericidal permeability increasing protein	Homo sapiens	128-131	
21838411-11	2011	RESULTS: Compared with placebo, duloxetine significantly improved the mean MADRS total score, BPI average pain rating, and SDS global functional impairment score (all p <= 0.05 for analyses described above).	Duloxetine Hydrochloride	32-42	bactericidal permeability increasing protein	Homo sapiens	94-97	
21838411-12	2011	The remission rate was significantly greater with duloxetine compared with placebo (p = 0.001) and was greater for duloxetine-treated patients with >=50% versus <50% improvement in BPI average pain score (p <= 0.001).	Duloxetine Hydrochloride	115-125	bactericidal permeability increasing protein	Homo sapiens	187-190